Delivery Order SPE2DB20D9214-SPE2DB25FD4WX
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,273.77 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a continuation of DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $18,019.40 by the Defense Logistics Agency (DLA) for the supply of Prolastin C 1,000 mg/20 ml vials. The contract employs firm fixed-price pricing with an ultimate completion date of September 8, 2025. This delivery order was issued without a set-aside designation, reflecting the company's competitive positioning within federal...
- The Defense Logistics Agency awarded a delivery order valued at $18,149.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. The award represents a discrete purchase order issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $15,753.25 by the Defense Logistics Agency on August 15, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries a firm fixed-price structure with an ultimate completion date of September 8, 2025, and no set-aside designation was applied to this award. This delivery order will be performed at the vendor's facility in...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $15,860.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $27,403.64 for Prolastin C 1,000 mg/20 ml vials. The award, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, carries no set-aside designation. The contract is funded through the Defense Logistics Agency's Medical Supply Chain operations, which serves as the government's primary source for...
- The Defense Logistics Agency awarded a $18,273.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4WXDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,238.39 by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Prolastin C 1,000 mg/20 mL vials. This firm fixed-price delivery order, with an ultimate completion date of August 29, 2025, represents a continuation of the company's role as a critical supplier within the federal pharmaceutical supply chain. The award carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive standing in federal procurement despite its small business status. The place of performance is located in Park Ridge, Illinois, where the company maintains its operational headquarters. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide. Prolastin C, an alpha-1 proteinase inhibitor therapy, represents one component of the extensive pharmaceutical portfolio the contractor supplies to Department of Defense healthcare sites. The DLA utilizes this IDC vehicle to procure branded and generic prescription drugs, biologics, and medical consumables necessary to support the medical supply requirements of military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.2k | 8/8/25 |